Mode
Text Size
Log in / Sign up
Phase 4 N=420 Randomized Single-blind Treatment

Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care

Intubation

Enrolled (actual)
420
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcome: Primary: Number of Participants Exhibiting Desaturation >5% — 73; 66 participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Succinylcholine (Drug); Rocuronium (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University Hospital, Basel, Switzerland
Primary completion
Aug 2006

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Exhibiting Desaturation >5%
73; 66
SECONDARY
Haemodynamic Sequelae of Intubation
SECONDARY
Time to Completion of Intubation
81; 95
SECONDARY
Quality of Intubation Conditions Using a Validated Score: Viby-Mogensen et al. Good Clinical Research Practice (GCRP) in Pharmacodynamic Studies of Neuromuscular Blocking Agents. Acta Anaesthesiol Scand 1996;40:59-74.
8.3; 8.2
SECONDARY
Number of Participants With an Failed First Intubation Attempts
32; 36

Summary

Emergency intubation of patients in intensive care is a high-risk endeavour. For many decades, succinylcholine has been the neuromuscular blocking agent of choice. However, succinylcholine may have life-threatening side effects and is contraindicated in a variety of diseases relevant in intensive care. The nondepolarizing agent rocuronium has been propagated as alternative for succinylcholine. Though a recent meta-analysis found no difference in intubating conditions between succinylcholine and rocuronium in elective cases, there are no data in emergent cases in intensive care. The aim of the present study is to compare succinylcholine and rocuronium with regard to 1) quality of intubating conditions, 2) length of the intubating sequence, 3) failed intubating attempts, 4) hemodynamic sequelae of intubation, and 5) desaturations.

Eligibility Criteria

Inclusion Criteria

  • indication for emergency intubation in intensive care
  • availability of qualified study physician

Exclusion Criteria

  • contraindication against succinylcholine or rocuronium
  • indication for awake fibreoptic intubation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00355368). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search